41. Giant cell arteritis Clinical trials / Disease details
Clinical trials : 131 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01450137 (ClinicalTrials.gov) | September 2011 | 3/10/2011 | Tocilizumab for Patients With Giant Cell Arteritis | A Phase II, Randomized, Double-blind, Placebo Controlled Study of Tocilizumab in Patients With Giant Cell Arteritis | Giant Cell Arteritis | Drug: Tocilizumab + Glucocorticoids (GCs);Drug: Placebo + Glucocorticoids (GCs) | University Hospital Inselspital, Berne | University of Bern;Roche Pharma AG | Completed | 50 Years | N/A | All | 30 | Phase 2 | Switzerland |